Fig. 6: Impact of the opposite targeting of p110δ and RhoA on the recruitment of macrophages to tumour sites and on ATX expression in SCC tumours.

a Representative images of immunohistochemical staining with anti-F4/80 antibody (left panels) or anti-ATX antibody (right panels) and Hematoxylin (blue) in representative sections of SCC tumours from NSG mice received no treatment (Control) or intravenous injections of WT macrophages and intratumoural injections of p190RhoGAP siRNA or intravenous injections of δ^D910A/D910A macrophages and intratumoural injections of p190RhoGAP siRNA. n = 8 mice/group. Scale bar = 50 μm. b Comparison of F4/80-positive cells in tumours from control mice or mice received intravenous injections of WT macrophages and intratumoural injections of p190RhoGAP siRNA or intravenous injections of δ^D910A/D910A macrophages and intratumoural injections of p190RhoGAP siRNA. c Comparison of ATX-positive cells in tumours from control mice or mice received intravenous injections of WT macrophages and intratumoural injections of p190RhoGAP siRNA or intravenous injections of δ^D910A/D910A macrophages and intratumoural injections of p190RhoGAP siRNA. All immunostainings were performed on tumour sections from tumours excised at the end point of each experiment. The symbols on the different groups denote data from eight fields/section of three sections of stained cells. All graphs represent the mean ± s.e.m. of three separate experiments. Statistically significant differences are indicated by * (P < 0.5) or ** (P < 0.01) or *** (P < 0.001), as determined by the ANOVA and Mann–Whitney U test.